Barry Douglas, MD
Plastic and Reconstructive Surgery · Garden City, NYNPI 1235108515
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (42.1%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 62.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $1,541 and has fallen 89.2% since, to $166 in 2025.
Across 55 payments — averaging $90.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sientra, Inc.$1K
- Mentor Worldwide LLC$545
- Avita Medical Americas, LLC$115
- Davol Inc.$52
- Galderma Laboratories, L.p.$46
- plus $81 from 4 others
What the payments were for
- Speaking & faculty fees$541%
- Grants$2,09542%
- Food & beverage$2,06241%
- Education$76915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $3,129 |
| Sientra, Inc. | 9 | $1,013 |
| Mentor Worldwide LLC | 15 | $545 |
| Avita Medical Americas, LLC | 2 | $115 |
| Davol Inc. | 2 | $52 |
| Galderma Laboratories, L.p. | 3 | $46 |
| Revance Therapeutics, Inc. | 1 | $41 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,980 in reported general payments places this provider in the 75th percentile of 219 plastic and reconstructive surgery providers in New York.
See all plastic and reconstructive surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefadroxil | 24 | $130 |
| ErythromycinErythromycin Base | 11 | $92 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $44 |
| Ondansetron OdtOndansetron | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Garden City
- Thomas DavenportGarden City$2.8M
- Matthew KilgoGarden City$14K
- Jerry ChangGarden City$14K
- Noel NatoliGarden City$11K
- Haritha VeeramachaneniGarden City$7K
- Finny GeorgeGarden City$6K
- Alexander DagumGarden City$5K
- Howard LangsteinRochester$350K
- James BradleyNew Hyde Park$306K
- David FuntWoodmere$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.